TITLE

Savient declares bankruptcy, will sell assets in $55M deal

AUTHOR(S)
Zanki, Tom
PUB. DATE
October 2013
SOURCE
njbiz;10/21/2013, Vol. 26 Issue 41, p19
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the Chapter 11 bankruptcy protection filed by Bridgewater, New Jersey-based Savient Pharmaceuticals Inc. agreeing to sell its assets worth of $55 million to Sloan Holdings CV, a subsidiary of WorldMeds.
ACCESSION #
91679916

 

Related Articles

  • Claims Deadline for JeffCo. Sigo, Shelly // Bond Buyer;4/19/2012, Vol. 380 Issue 33700, p9 

    The article reports on the deadline set by the federal judge overseeing the bankruptcy case in Jefferson County, Alabama for creditors to file proof of claims.

  • KRYSTEXXA.  // MPR - Urologists' Edition;Fall2010/Winter2011, Vol. 7 Issue 1, pA5 

    The article offers brief information on Krystexxa, a PEGylated uric acid specific enzyme from Savient Pharmaceuticals Inc. which can be used for treatment of chronic gout in adult patients.

  • Best Professional Sales Aid.  // Medical Marketing & Media;Nov2011 Awards, p29 

    The article announces that the Krystexxa Sales Aid of Health 4 Brands and Savient Pharmaceuticals Inc. and the Right Fit aid of ICC and Sunovion Pharmaceuticals Inc. had received the Gold Award and Silver Award, respectively, for the Best Professional Sales Aid.

  • Tread carefully before seeking payment in bankruptcy cases. Wheeler, Ann Marie Nancy // Counseling Today;Nov2016, Vol. 59 Issue 5, p14 

    The article provides an answer to a question of the considerations before deciding to file proofs of claim in a client's or parent's guardian's bankruptcy proceedings.

  • Financings Roundup.  // BioWorld Today;2/2/2011, Vol. 22 Issue 22, p7 

    The article reports on convertible senior notes priced by Savient Pharmaceuticals Inc.

  • No Sale for Savient: Shares Spiral Downward 44.4%.  // Bioworld Week;11/1/2010, Vol. 18 Issue 44, p3 

    The article reports on the 44.4% decline in Savient Pharmaceuticals Inc.'s shares on October 25, 2010 after its failure to find a buyer.

  • Earnings Roundup.  // BioWorld Today;8/5/2011, Vol. 22 Issue 151, p4 

    The article reports on the net loss posted by Savient Pharmaceuticals Inc. during the second quarter of 2011.

  • Earnings Roundup.  // BioWorld Today;11/4/2011, Vol. 22 Issue 215, p7 

    The article reports on the financial performance of Savient Pharmaceuticals Inc. of East Brunswick, New Jersey for the third quarter of 2011.

  • Boost for Savient as drug gets key code. Kaitwasser, Jared // njbiz;1/16/2012, Vol. 25 Issue 3, p3 

    The article reports that Savient Pharmaceuticals Inc. gained a billing code for its refractory chronic gout drug Krystexxa from the U.S. Centers for Medicare and Medicaid Services.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics